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Abstract
Bioactive glass ceramics (BGCs) have been used in orthopedic and dentistry due 
to having better osteoconductive and osteostimulative properties. This study aimed 
to evaluate and compare the drug release properties of two different BGCs; 45S5 
and S53P4. The BGCs were composed with four phases of SiO2 – CaO – Na2O – P2O5 
system, synthesized by sol–gel method using dual templates; a block-copolymer as 
mesoporous templates and polymer colloidal crystals as macroporous templates, 
called three-dimensionally ordered macroporous-mesoporous bioactive glass 
ceramics (3DOM-MBGCs). In vitro bioactivity test performed by soaking the 
3DOM-MBGCs in simulated body fluid (SBF) at 37°C. The results indicated that, 
the 45S5 have the ability to grow hydroxyapatite-like layer on the surfaces faster 
than S53P4. Gentamicin drug was used to examine in vitro drug release properties 
in phosphate buffer solution (PBS). The amount of drug release was quantified 
through UV/Vis spectroscopy by using o-phthaldialdehyde reagent. S53P4 showed 
high drug loading content. The outcome of drug release in PBS showed that both 
S53P4 and 45S5 exhibited a slowly continuous gentamicin release. The resultant 
drug release profiles were fitted to the Peppas-Korsmeyer model to establish the 
predominant drug release mechanisms, which revealed that the kinetics of drug 
release from the glasses mostly dominated by Fickian diffusion mechanism.
Keywords: macroporous, mesoporous, ceramics, bioactive glasses, drug release, 
sol–gel process
1. Introduction
Bone is the second most widely transplanted tissue after blood. More than 2.2 
million bone graft operations are performed annually worldwide in order to repair 
bone defects in orthopedics and dentistry [1]. Bioactive glass ceramics (BGCs) are 
one of the most promising synthetic bone replacements come regeneration material 
which has the ability to chemically bond with living bone tissue and stimulate bone 
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growth without promoting inflammation or toxicity, developed by Larry Hench at 
the University of Florida in 1969 [1–4]. In early the heated glass powder, the micro-
composite between apatite and β-wollastonite (CaO·SiO2) within a homogenous 
glassy phase showed not only a bioactivity but also high mechanical strength [4]. This 
BGCs was called A/W derived from the names of crystalline phase. The bioactivity 
of glass ceramics is believed to be due to the dissolution of calcium from wollastonite 
and/or the glassy phase. In case of treating bone defect, the bone regeneration rate 
depends on the material’s composition [5]. Hydroxyapatite (HA) is the inorganic part 
of human bone [6]. The bonding with bone process is associated with the formation 
of HA layer on the implant’s surface [7]. BGCs can either be synthesized by the melt 
quenching or sol–gel method. Early BGCs were prepared by the melt quenching 
method. Sol–gel processing was started practicing in early 1990s for bioactive glass 
synthesis. Sol–gel derived bioactive glasses are made of a colloidal silica solution syn-
thesized by the hydrolysis of alkoxide precursor to form a sol. Tetraethyl orthosilicate 
(TEOS) is commonly used as silica precursor, Triethyl phosphate (TEP) is used to 
add phosphate, salt calcium nitrate used to introduce calcium and Na2O included to 
decrease the melting temperature [8, 9]. Sol–gel derived bioactive glasses can provide 
higher surface Si-OH groups, which promote active places for more functionaliza-
tion. The greater specific surface area that enhance the rate of hydroxyapatite 
formation is considerably higher degree of bioactivity compare to the melt quenching 
process [10–12]. Mesoporous bioactive glass ceramics (MBGCs) are considered the 
third-generation bioactive glasses were developed in 2004 by the combination of 
sol–gel method. MBGCs can possess more optimal surface area, ordered mesoporous 
structure, variable pore size and volume, improved in in vitro apatite mineralization 
in simulated body fluid (SBF) comparing with non-mesoporous bioactive glasses 
(NBG) [13]. However, BGCs having higher specific surface area and pore volume 
accelerates the hydroxyapatite formation and increase prolong the bioactive behavior 
[9]. MBGCs also get focused because of having more potential applications, such 
as catalysis, adsorption/separation, nanomaterial synthesis and also in biomaterial 
science as bone scaffolds for drug delivery and bone regeneration [9].
Mesoporous bioactive glass ceramic (MBGC) has brought a significant revolution 
in material science in terms of drug delivery. MBGC has some important properties 
which make itself more potential for drug delivery, such as well-ordered pores, large 
pore volumes and high specific surface area. As a result, MBGCs can easily entrap the 
drug molecules with its highly ordered mesoporous channel with a pore range of 2 to 
50 nm [12, 14–17]. These characteristics greatly enhance MBGC for bone forming bio-
activity, higher drug loading efficiency and lower drug release kinetics comparing with 
conventional BGCs [18–21]. Moreover, the mesosized pore are too small to promote 
cell growth. To overcome this limitation, the macroporous networks was studied and it 
suitable for tissue scaffolds that mimic the structure of porous bone structure [1].
Sol–gel technology is a wonderful progression in science with various applica-
tions since 1800s [12]. It is the process of making ceramic and glass materials using 
relatively low temperature hydrolysis and condensation reaction followed aging, 
drying and thermal stabilization [1]. Use of different surfactants (eg: P123, F127) 
during MBGCs preparation amplify the pore volume and surface area, which 
enhance the drug loading efficiency [16]. 45S5 and S53P4 bioactive glasses with a 
system of SiO2-Na2O-CaO-P2O5 considered more attention for bone tissue regenera-
tion and regeneration properties due to their excellent bioactivity, biocompatibility, 
osteogenic and angiogenic effects [4, 18, 22–24]. Perioglas® was the first com-
mercial product of 45S5 glasses, later reestablished by NovaBone® and BoneAlive® 
commercialized with composition of S53P4 [4].
Conventional treatment of bone infections like osteomyelitis involves surgery 
to remove necrotic bone tissue and repeated irrigations combined with the use of 
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systemic antibiotics administration, wound drainage and implant removal. Systemic 
therapy of antibiotics has various adverse effects and risk of developing bacterial 
resistance to drugs. Local drug delivery system solves the problems by providing 
more advantages including high drug delivery efficiency, continuous action, reduced 
toxicity and convenience to the patients. Administration of single dose of localized 
drug with desired therapeutic range can reduce the need for follow-up care, reduce 
the risk of side effects, toxicity and increase patient compliance [19, 20, 25].
In our study, the hierarchically macroporous structured and mesosized pores 
of 45S5 and S53P4 BGCs were synthesized by sol–gel method and evaluated their 
in vitro bioactivity. The bioactivity effects of both bioactive glasses were investi-
gated in SBF solution. The in vitro drug release properties in PBS were evaluated. 
Gentamicin sulfate (GS) was chosen as a model drug to encapsulation in the 
MBGCs to obtain a drug delivery system. GS is a broad-spectrum bactericidal 
antibiotic belonging aminoglycoside class; antibacterial activity is due to its ability 
to irreversibly bind ribosomes and half bacterial protein synthesis. GS vastly used 
in orthopedic treatments [26–28].
2. Experimental
2.1 Materials
Calcium nitrate tetrahydrate (CNT; Ca(NO3)2.4H2O), tetraethyl orthosilicate 
(TEOS; Si(OC4H9)4, 98%), triethyl phosphate (TEP; P(OEt)3, 99%) were purchased 
from Acros Organic, sodium nitrate (NaNO3), nitric acid (HNO3) were purchased 
from Merck, Germany, the surfactant Pluronic P123 (EO20-PO70-EO20, average 
Mn ~ 5800) were produced from Sigma-Aldrich, Germany. Gentamicin was obtained 
from Fuan Pharmaceutical group Yantai Co., LTD. Polymethylmethacrylate (PMMA) 
colloidal crystals with 300 nm size were prepared by our previous worked [29].
2.2 Preparation of bioactive glass ceramics
Two different 3DOM-MBGCs; 45S5 and S53P4 were synthesized via sol–gel 
method follow by published work [30]. The synthesis process went through hydro-
lysis and polycondensation of TEOS, TEP, CNT and NaNO3 (Figure 1) with the 
appropriate mol ratio mentioned in Table 1. HNO3 was used to catalyze the hydro-
lysis process and non-ionic block copolymer P123 was chosen as structure-directing 
agent. The solution was vigorously stirred (700 rpm) at room temperature to obtain 
a clear sol (hydrolysis reaction) and further stirred to reach the gel point (con-
densation reaction). To obtain 3DOM structure, a monolithic piece of the PMMA 
colloidal crystal templates were completely immersed in the sol and excess solution 
was removed. The products were aged in sealed vials at 45°C for 24 h to allow the 
polycondensation reaction followed by a drying process at 45°C for 24 h to eliminate 
excess solvents and by products. Finally, the samples were stabilized at 600°C in 
air for 4 h with a fixed heating rate of 2°C/min. The morphology of the bioactive 
glasses was analyzed in detail by scanning electron microscopy (SEM). Their 
element compositions were characterized by energy dispersive spectroscopy (EDS) 
attached to the SEM with Silicon crystal detectors. Fourier Transform Infrared 
Spectroscopy (FTIR) was carried out in the transmission mode with mid-infrared 
range 400–4000 cm−1 at a resolution of 4 cm−1 by using the KBr pellet method. The 
N2 adsorption–desorption measurements carried out by Brunauer–Emmett–Teller 




2.3 Assessment of in vitro bioactivity test
The bioactivity of the obtained samples was examined using in vitro test by 
immerging the samples in SBF solution at body temperature, 37°C at pH 7.40 
following Kokubo method [31]. The in vitro bioactivity was performed by soaking 
grainy 3DOM-MBGCs in the SBF solution at a temperature of 37.0°C for 1, 2, 3 and 
7 days with daily refreshing of the SBF solution. The ratio of the glass powders 
weight to SBF volume was 1.5 mg/mL. After soaking, samples were removed from 
the SBF solution and washed with deionized water several times and air-dried at 
room temperature. The changes of the bioactive glass surfaces were examined by 
SEM and FTIR techniques.
2.4 In vitro study of drug release
2.4.1 Determination of drug concentration
Gentamicin concentration was analyzed by measuring the UV/Vis absorbance 
of gentamicin-o-phthaldialdehyde complex at 333 nm [14]. The o-phthaldialdehyde 
reagent was prepared according to Huang et al., 2017 [17]. 1 mL of gentamicin 
solution, 1 mL of isopropanol and 1 mL of o-phthaldialdehyde reagent were reacted 
for 45 min at room temperature to prepare the sample to examine in UV/visible 
Figure 1. 
Synthesis of 3DOM-MBGCs via sol–gel method.
Reagents Compositions
45S5 S53P4
TEOS (SiC8H20O4) 45% SiO2 53% SiO2
TEP (C6H15O4P) 6% P2O5 4% P2O5
Ca(NO3)2.4H2O 24.5% CaO 20% CaO
NaNO3 24.5% Na2O 23% Na2O
Table 1. 
Chemicals used in synthesis of 45S5 and S53P4 3DOM-MBGCs.
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spectroscopy [32]. Before determination, a calibration curve (R2 = 0.99) was 
made for each set of measurements and determined by taking absorbance vs. drug 
concentration between 1 to 150 ppm as parameters.
2.4.2 Encapsulation of gentamicin in the bioactive glass ceramics
Encapsulation of gentamicin into the MBGCs (45S5 and S53P4) were carried out 
in PBS pH 7.4 at room temperature for 24 h. 200 mg of each MBGCs was immersed 
in 10 mL of PBS containing gentamicin with a concentration of 10 mg/mL and 
stirred for 24 h. After that, the drug loaded MBGCs were filtered and then the 
drug loading efficiency and drug loading content were determined. Drug loading 
efficiency was measured by depletion method, by determining the difference in 
gentamicin concentration in the loading medium before and after loading [14]. The 
drug-loading experiments were carried out in triplicate, and the statistical com-
putations were performed with the IBM SPSS Statistics version 25. Drug loading 
efficiency and drug loading content are two important parameters for drug delivery 
study with MBGCs. Drug loading content represents the mass ratio of drugs in drug 
loaded MBGCs and drug loading efficiency reflects the utilization of drugs in feed 
during drug loading [33]. The drug loading efficiency and drug loading content are 
expressed according to the following Equations [33].
 ( ) Mass of the drug in MBGCsDrug loading efficiency .% 100
Mass of the drug in feed
wt x=  (1)
 ( ) Mass of the drug in MBGCsDrug loading content .% 100
Initial mass of MBGCs
wt x=  (2)
2.4.3 In vitro drug release
50 mg of drug loaded MBGCs were placed into 10 mL of PBS and subsequently 
agitated in a horizontal shaking incubator at 37°C. 2 mL of release medium was 
withdrawn at predetermined time intervals and replaced with fresh release medium 
(2 mL) at each measurement. The triplicate samples of each drug loaded MBGCs 
(45S5 and S53P4) were used to determine the drug release profile.
2.4.4 Kinetic analysis drug release profile
To study the drug release kinetic from 45S5 and S53P4 MBGCs, the in vitro drug 







Where K is the Peppas-Korsmeyer constant, tM
M∞
 is the fractional solute release 
at time t, and n is the exponent indicative of the release mechanism. An exponential 
value in the range of 0.45 or less and 0.89 or above indicate respectively Fickian 
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diffusion and case II transport (typical zero-order release). Values between 0.45 
and 0.89 indicate non-Fickian or anomalous release by both diffusion and erosion 
release [34].
3. Results and discussion
3.1 Morphology and microstructure of bioactive glass ceramics
Figure 2 shows the SEM image and EDS spectra of (a) 45S5 and (b) S53P4 
3DOM-MBGCs. Bioactive glass with hierarchical porosity was formed through 
the PMMA and Pluronic P123 dual templating system. The SEM image of 53S4P 
(Figure 2(b)) shows more well ordered macroporous structure with spherical pores 
are around 300 nm. While, 45S5 shows distorted 3DOM structure (Figure 2(a)). 
The EDS spectrum of 45S5 and S53P4 in Figure 2 shows the peaks corresponding to 
Si, Ca, Na and O that represent the preservation of the elements in the precursors 
without impurity elements. The FTIR spectra of 45S5 and S53P4 3DOM-MBGCs 
in Figure 3 exhibits the characteristic peaks of Si-O-Si bending, symmetric and 
asymmetric stretching vibration at 467, 802 and 1086 cm−1, respectively. In the peak 
at 564 and 950 cm−1 corresponding to the P-O bending and stretching vibration, 
respectively. In addition, the peak at 1635 and 3450 cm−1 correlates to O-H bonds 
indicates the water trapped inside the sample. The narrow band near 1384 cm−1 
indicates the characteristic of the carbonate group (CO3
2−) [35]. Figure 4 indicates 
that all the BET curves of the 45S5 and S53P4 MBGCs presented a type IV isotherms 
Figure 2. 
SEM and EDS spectra of (a) 45S5 and (b) S53P4 3DOM-MBGCs.
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pattern with type H4 hysteresis loops, characterizing mesoporous materials with 
narrow slit-like pores, with internal voids of irregular shape and broad size dis-
tribution [36]. This is confirmed by the average data of specific surface area, pore 
volume and pore diameter of 45S5 and S53P4 3DOM-MBGCs listed in Table 2. The  
bioactive glasses show specific surface area in range of 96.54 to 116.76 m2/g. 
The 45S5 glasses shows a relatively wide pore size distribution calculated from 
the adsorption branch using the BJH model, and the average pore size is around 
15.158 nm, while the S53P4 glasses gained average pore size around 11.230 nm.
3.2 Assessment of in vitro bioactivity test
The in vitro bioactivity of 3DOM-MBGCs was tested at body temperature 
of 37°C by using the SBF solution whose composition and ionic concentration 
similar to human blood plasma. Figure 5 shows the SEM images of 45S5 bioac-
tive glasses having different soaking time in SBF solutions. Compared with the 
morphology of the prepared bioactive glasses in Figure 5a, the nucleation of 
hydroxyapatite occurred on the glass surfaces after soaking in the SBF solution 
for 2 days (Figure 5c). The surface of 45S5 glasses were covered by precipitation 
of apatite-like layer more than 3 days soaking in SBF solution (Figure 5d-f). 
Figure 6, the formation of hydroxyapatite-like on the surface of S53P4 glasses 
started after 3 days of immersion in SBF solution. Within 7 days, most of the 
glass surfaces were covered by the apatite-like layer (Figure 6d). 45S5 showed 
fast hydroxyapatite-like precipitation than S53P4. However, the hydroxyapatite 
formation depends on the incorporation of Ca2+ and PO4
3− on the MBG’s glass 
surfaces during bioactivity test. Lower SiO2 and higher CaO, P2O5 content in 45S5 
could amplify the rate of hydroxyapatite formation on MBG’s glass surfaces. The 
chemical composition and the microstructural morphology of 3DOM-MBGCs 
directly related to their bioactivity. The SBF can easier penetrate the larger 
macropores in the 3DOM bioactive glass compared to the mesopores in bioactive 
glasses [37]. Therefore, the minor difference average surface area and pore size of 
3DOM-MBGCs (Table 3) has no effect in determining apatite growth. Due to both 
3DOM-MBGCs using the same size of PMMA spheres for macroporous and same 
surfactant for mesoporous.
Figure 3. 
FTIR spectra of (a) 45S5 and (b) S53P4 3DOM-MBGCs. Copyright [30].
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The FTIR spectra of 45S5 in Figure 7, at below spectrum, the sample before 
soaking in SBF solution exhibits the peaks at 467, 802 and 1086 cm−1 correspond-
ing to the vibration of Si-O-Si bond, bending, symmetric and asymmetric stretch-
ing vibration, respectively. In vibrational peak at 564 and 950 cm−1 correlates to 
the P-O vibrational peak. In addition, the O-H bonds of the water trapped inside 
Figure 4. 
N2 adsorption–desorption isotherms and pore size distribution of (a) 45S5 and (b) S53P4 3DOM-MBGCs. 
Copyright [30].
Samples Surface area (m2/g) Pore Volume (cm3/g) Pore Diameter (Å)
45S5 96.54 0.365 151.58
S53P4 116.76 0.327 112.30
Table 2. 
The average data of specific surface area, pore volume and pore diameter of 45S5 and S53P4 3DOM-MBGCs. 
Copyright [30].
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Figure 5. 
SEM images of 45S5 bioactive glass ceramics (a) before soaking in SBF solution and after soaking in SBF solution 
for (b) 1 day (c) 2 days (d) 3 days (e) 7 days and (f) 7 days with higher magnification. Copyright [30].
Figure 6. 
SEM images of S53P4 bioactive glass ceramics (a) before soaking in SBF solution and after soaking in SBF for 
(b) 1 day (c) 2 days (d) 3 days (e) 7 days and (f) 7 days with higher magnification. Copyright [30].
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the sample was shown at 1635 and 3450 cm−1. The narrow band near 1384 cm−1 
indicates the characteristic of the carbonate group (CO3
2−) [35]. After the soaking 
in SBF, all the characteristic peaks are still observed. The P-O peak at 564 splits 
into doublet peak at 586 and 564 cm−1 which normally appears after immersion 
of the bioactive glass in SBF solution15. All the bands corresponding to the P-O 
represent the formation of hydroxyapatite on the surface of MBGCs. Figure 8 
represents the FTIR spectra of S53P4 bioactive glasses. The sample before soak-
ing in SBF solution shows peaks at 467, 1087 and the shoulder at 1087–1250 cm−1 




The drug loading efficiency and content of 45S5 and S53P4.
Figure 7. 
FTIR spectra of 45S5 bioactive glass ceramics with different soaking time in SBF solution. Copyright [30].
Figure 8. 
FTIR spectra of S53P4 bioactive glass ceramics with different soaking time in SBF solution. Copyright [30].
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correlates to the vibration of Si-O-Si bond. The peaks at 1385 and 1401 cm−1 indi-
cates the characteristics of carbonate group (CO3
2−) [35]. In the peak around 576 
and 966 cm−1 corresponding to the P-O bending and stretching vibration, respec-
tively. In addition, the peak at 1631 and 3445 cm−1 correlated to O-H bonds. After 
S53P4 MBGCs were soaked in SBF for 1 day, the aforementioned vibrational peaks 
are still observed. The P-O peak at at 607 and 567 cm−1, which confirmed that the 
formation of amorphous phosphate phase on the glass surface [29]. Although, the 
splitting P-O peak of S53P4 appears in 1 day after soaking in SBF, while in the case 
of 45S5 after soaking for 2 days. However, the formation of hydroxyapatite-like on 
the surface of S53P4 glasses started after 3 days of soaking in SBF solution, slowly 
growth comparing with 45S5, indicated the better bioactivity of 45S5 than S53P4 
bioactive glasses.
3.3 In vitro study of drug release
3.3.1 Drug loading
The drug loading efficiency and drug loading content of both MBGCs are sum-
marized in Table 3. The drug loading efficiency in 45S5 was 18.00 ± 3.16%, while 
S53P4 showed quite higher drug loading efficiency of about 22.14 ± 2.53%. However, 
the loading efficiency of S53P4 was not statistically different from that of 45S5 
(independent t-test, p > 0.05). The drug loading content of the MBGCs was found 
to be 8.74 ± 1.09 wt% for 45S5 and 11.91 ± 2.09 wt% for S53P4 glasses. The signifi-
cant difference was not observed for the drug loading content of 45S5 from S53P4 
(independent t-test, p > 0.05). S53P4 provides high average drug-loading content 
compared with other inert carrier materials that generally have low drug-loading 
content (less than 10 wt%) [33]. The porous materials can be developed to fabricate 
high drug-loading carriers due to their promising intrinsic properties, such as large 
hollow interior, porous surface, high surface area and large pore volume [33]. The 
good drug-loading capacity obtained in this study could be related to high surface 
area of the carrier with porous structure as supported by the results obtained from 
N2 adsorption desorption analysis.
3.3.2 In vitro drug release
The release profiles for gentamicin from the MBGCs to the PBS are represented 
in Figure 9. For both MBGCs, the release of gentamicin showed an initial fast 
release followed by a relatively slow subsequent release. An initial fast release of 
the antibiotic was observed during the first 24 hours of soaking, reaching the mean 
gentamicin release values of 34.53% (45S5) and 41.21% (S53P4). The subsequent 
release rate was quite low in comparison with the first period. However, the S53P4 
bioactive glasses showed a higher initial drug release behavior than 45S5 glasses. 
But later, both bioactive glasses reached the same point after 96 hours of release 
values of 64.27% (45S5) and 64.53% (S53P4). Both S53P4 and 45S5 bioactive glasses 
showed a slowly continuous gentamicin release.
To study the mechanism of drug release from the MBGCs, the first 60% of 
gentamicin release profile was fitted in Peppas-Korsmeyer model. In this model, 
the value of n characterizes the release mechanism of drug as described in Table 4. 
As observed in Table 4, the n values of the release data of 45S5 and S53P4 glasses 
are 0.3992 and 0.3004, respectively. This indicated that the drug release from both 
systems can be described by Fickian diffusion [34]. Both MBGCs possessed porous 
structures with hollow interiors. The diffusion through channel might dominate the 




3DOM-MBGCs were synthesized successfully by the sol–gel method using 
spherical PMMA colloidal crystals of 300 nm and non-ionic block copolymer 
P123 as cotamplates. The morphology of S53P4 bioactive glass revealed well-
ordered macroporous structure with larger surface area. While, 45S5 bioactive 
glass had shown distorted 3DOM structure with a bit higher pore diameter. Base 
on the SEM and FTIR results indicated the better bioactivity of 45S5 than S53P4 
bioactive glass ceramics which was able to initiate the formation of hydroxyapa-
tite-like layer on glass surface after soaking in SBF solution within 2 days (45S5) 
and 3 days (S53P4). The drug delivery system based on 45S5 and S53P4 3DOM-
MBGCs have been synthesized, and the release behavior of both porous bioactive 
glasses were studied. The results indicated that the S53P4 glasses showed higher 
drug loading efficiency and gave relatively initial fast release compared to the 
45S5 due to its high surface area. Even though, the drug loading content was not 
significant different from that of both bioactive glass ceramics. The resultant 
drug release mechanism was occupied from the first 60% of gentamicin release 
profile fitted to the Peppas-Korsmeyer model, which clarified that the kinetics 
of drug release from the bioactive glass ceramics mostly occurred by Fickian 
diffusion mechanism.
Therefore, the results indicated the bioactivity and drug release profile of meso-
porous bioactive glass ceramics which can accelerate the bone growth or new bone 
formation and could be a use as a promising drug release system for bone implant 
materials preparation.
Figure 9. 






45S5 0.0204 0.3992 0.95
S53P4 0.0466 0.3004 0.99
Table 4. 
Kinetic assessment of gentamicin release data of 45S5 and S53P4 in PBS (Peppas-Korsmeyer model).
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